Orlov S. Nicole Schaeffer Sells 1,642 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Orlov S. Nicole Schaeffer sold 1,642 shares of the firm’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $71.50, for a total value of $117,403.00. Following the completion of the sale, the insider now owns 118,579 shares of the company’s stock, valued at approximately $8,478,398.50. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Insmed Stock Up 0.8%

Shares of NASDAQ INSM opened at $73.69 on Thursday. Insmed Incorporated has a 52-week low of $55.74 and a 52-week high of $84.91. The firm has a market capitalization of $13.42 billion, a price-to-earnings ratio of -13.18 and a beta of 0.84. The stock has a 50 day moving average price of $69.32 and a 200 day moving average price of $72.99. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. During the same quarter in the prior year, the company posted ($1.06) earnings per share. Insmed’s quarterly revenue was up 22.9% compared to the same quarter last year. Sell-side analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of analyst reports. Bank of America boosted their price objective on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. Stifel Nicolaus cut their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, UBS Group reduced their price target on Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $96.73.

Institutional Trading of Insmed

A number of hedge funds have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. increased its position in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP purchased a new stake in shares of Insmed in the 4th quarter worth approximately $28,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period. Finally, Spire Wealth Management purchased a new position in Insmed during the fourth quarter valued at approximately $47,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.